文献速递妇科

塞法迪犹太女性中基于人群的BRCA1奠基者突变检测的成本效益

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
PubMed 文献 · Am J Obstet Gynecol · 2017-12-26

本研究构建Markov模型,比较对≥30岁塞法迪犹太女性进行基于人群的BRCA1检测与基于家族史临床标准检测的终身成本与效果。基于人群检测使预期寿命增加12个月(质量调整生命年=1.00),英国增量成本效益比为67.04英镑/质量调整生命年,美国为308.42美元/质量调整生命年,概率敏感性分析显示100%模拟在支付阈值下具有成本效益。

要点

  • 基于人群的BRCA1检测使塞法迪犹太女性预期寿命增加12个月(质量调整生命年=1.00)。
  • 英国增量成本效益比为67.04英镑/质量调整生命年,美国为308.42美元/质量调整生命年。
  • 概率敏感性分析显示100%模拟在英国20000英镑/质量调整生命年和美国100000美元/质量调整生命年支付阈值下具有成本效益。

核心结论

  • 在塞法迪犹太女性中,基于人群的BRCA1检测与临床标准驱动的方法相比具有高度成本效益。
  • 这支持将犹太人群的BRCA检测模式转变为基于人群的检测,无论阿什肯纳兹或塞法迪血统。

研究设计与样本

  • 构建Markov模型,比较基于人群的BRCA1检测与基于家族史临床标准检测在≥30岁塞法迪犹太女性中的终身成本与效果。
  • BRCA1携带者接受磁共振成像/乳房X线摄影和降低风险手术。
  • 成本以2015年价格报告,所有成本和结局按3.5%贴现,时间范围为终身,视角为支付方。

主要发现

  • 基于人群检测使预期寿命增加12个月(质量调整生命年=1.00)。
  • 英国基于人群检测的基线贴现增量成本效益比为67.04英镑/质量调整生命年,美国为308.42美元/质量调整生命年。
  • 单因素敏感性分析结果稳健。
  • 概率敏感性分析显示100%模拟在英国20000英镑/质量调整生命年支付阈值下具有成本效益,在美国100000美元/质量调整生命年支付阈值下具有成本效益。
  • 情景分析显示,即使绝经前卵巢切除术不降低乳腺癌风险或激素替代治疗依从性为零,基于人群检测在英国和美国人群中仍具有成本效益。

关键数值与推荐

  • 塞法迪犹太人群中BRCA突变总体患病率为0.7%,阿什肯纳兹犹太人群中为2.5%。
  • 仅185delAG(c.68_69delAG)一个BRCA1/BRCA2奠基者突变见于塞法迪犹太人群。

临床怎么用

  • 作者认为,在犹太人群中,无论阿什肯纳兹或塞法迪血统,应支持将BRCA检测模式转变为基于人群的检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effective compared with family history based testing in Ashkenazi Jewish women. However, only 1 of the 3 Ashkenazi Jewish BRCA1/BRCA2 founder mutations (185delAG[c.68_69delAG]), 5382insC[c.5266dupC]), and 6174delT[c.5946delT]) is found in the Sephardi Jewish population (185delAG[c.68_69delAG]), and the overall prevalence of BRCA mutations in the Sephardi Jewish population is accordingly lower (0.7% compared with 2.5% in the Ashkenazi Jewish population). Cost-effectiveness analyses of BRCA testing have not previously been performed at these lower BRCA prevalence levels seen in the Sephardi Jewish population. Here we present a cost-effectiveness analysis for UK and US populations comparing population testing with clinical criteria/family history-based testing in Sephardi Jewish women. STUDY DESIGN: A Markov model was built comparing the lifetime costs and effects of population-based BRCA1 testing, with testing using family history-based clinical criteria in Sephardi Jewish women aged ≥30 years. BRCA1 carriers identified were offered magnetic resonance imaging/mammograms and risk-reducing surgery. Costs are reported at 2015 prices. Outcomes include breast cancer, ovarian cancer, and excess deaths from heart disease. All costs and outcomes are discounted at 3.5%. The time horizon is lifetime, and perspective is payer. The incremental cost-effectiveness ratio per quality-adjusted life-year was calculated. Parameter uncertainty was evaluated through 1-way and probabilistic sensitivity analysis. RESULTS: Population testing resulted in gain in life expectancy of 12 months (quality-adjusted life-year = 1.00). The baseline discounted incremental cost-effectiveness ratio for UK population-based testing was £67.04/quality-adjusted life-year and for US population was $308.42/quality-adjusted life-year. Results were robust in the 1-way sensitivity analysis. The probabilistic sensitivity analysis showed 100% of simulations were cost effective at £20,000/quality-adjusted life-year UK and the $100,000/quality-adjusted life-year US willingness-to-pay thresholds. Scenario analysis showed that population testing remains cost effective in UK and US populations, even if premenopausal oophorectomy does not reduce breast cancer risk or if hormone replacement therapy compliance is nil. CONCLUSION: Population-based BRCA1 testing is highly cost effective compared with clinical criteria-driven approach in Sephardi Jewish women. This supports changing the paradigm to population-based BRCA testing in the Jewish population, regardless of Ashkenazi/Sephardi ancestry.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Patel S, Legood R, Evans DG, et al. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. Am J Obstet Gynecol. 2017. PMID: 29288066. doi:10.1016/j.ajog.2017.12.221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。